Acute respiratory distress syndrome future or investigational therapies: Difference between revisions
No edit summary |
|||
| Line 14: | Line 14: | ||
[[Macrolide|'''Macrolide antibiotics''']]: | [[Macrolide|'''Macrolide antibiotics''']]: | ||
*An observational study of 47 patients with [[Acute respiratory distress syndrome historical perspective|acute lung injury (ALI)]] demonstrated an association between administration of macrolide antibiotics and both early discontinuation of [[mechanical ventilation]] as well as improved survival at 180 | *An observational study of 47 patients with [[Acute respiratory distress syndrome historical perspective|acute lung injury (ALI)]] demonstrated an association between administration of macrolide antibiotics and both early discontinuation of [[mechanical ventilation]] as well as improved survival at 180 days<ref name="pmid22116799">{{cite journal| author=Walkey AJ, Wiener RS| title=Macrolide antibiotics and survival in patients with acute lung injury. | journal=Chest | year= 2012 | volume= 141 | issue= 5 | pages= 1153-9 | pmid=22116799 | doi=10.1378/chest.11-1908 | pmc=3342785 | url=http://www.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pubmed&tool=sumsearch.org/cite&retmode=ref&cmd=prlinks&id=22116799 }} </ref> | ||
==References== | ==References== | ||
Revision as of 05:50, 30 June 2016
|
Acute respiratory distress syndrome Microchapters |
|
Differentiating Acute respiratory distress syndrome from other Diseases |
|---|
|
Diagnosis |
|
Treatment |
|
Case Studies |
|
Acute respiratory distress syndrome future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Acute respiratory distress syndrome future or investigational therapies |
|
FDA on Acute respiratory distress syndrome future or investigational therapies |
|
CDC on Acute respiratory distress syndrome future or investigational therapies |
|
Acute respiratory distress syndrome future or investigational therapies in the news |
|
Blogs on Acute respiratory distress syndrome future or investigational therapies |
|
Directions to Hospitals Treating Acute respiratory distress syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1], Associate Editor(s)-in-Chief: Brian Shaller, M.D. [2]
Overview
Several medical therapies, including granulocyte macrophage colony stimulating factor (GM-CSF) are currently under investigation as potential treatments for ARDS.
Investigational therapies
Granulocyte macrophage colony stimulating factor (GM-CSF):
- An observational study found an association between higher levels of GM-CSF in brochoalveolar lavage (BAL) fluid and improved survival in patients with ARDS[1]
- A study of 6 patients with ARDS due to pneumonia who were administered nebulized GM-CSF demonstrated improvements in lung compliance and mortality scores; 4 of 6 patients survived to discharge[2]
- A randomized clinical trial (RCT) is currently underway to further study the potential efficacy of inhaled GM-CSF in ARDS
- An observational study of 47 patients with acute lung injury (ALI) demonstrated an association between administration of macrolide antibiotics and both early discontinuation of mechanical ventilation as well as improved survival at 180 days[3]
References
- ↑ Matute-Bello G, Liles WC, Radella F, Steinberg KP, Ruzinski JT, Hudson LD; et al. (2000). "Modulation of neutrophil apoptosis by granulocyte colony-stimulating factor and granulocyte/macrophage colony-stimulating factor during the course of acute respiratory distress syndrome". Crit Care Med. 28 (1): 1–7. PMID 10667491.
- ↑ Herold S, Hoegner K, Vadász I, Gessler T, Wilhelm J, Mayer K; et al. (2014). "Inhaled granulocyte/macrophage colony-stimulating factor as treatment of pneumonia-associated acute respiratory distress syndrome". Am J Respir Crit Care Med. 189 (5): 609–11. doi:10.1164/rccm.201311-2041LE. PMID 24579839.
- ↑ Walkey AJ, Wiener RS (2012). "Macrolide antibiotics and survival in patients with acute lung injury". Chest. 141 (5): 1153–9. doi:10.1378/chest.11-1908. PMC 3342785. PMID 22116799.